Chimeric Therapeutics Ltd has released a press release.
Chimeric Therapeutics: Final Results in Phase 1 Trial of CORE NK Platform
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Chimeric Therapeutics
- Chimeric partners with be the match biotherapies
- Successful completion of Institutional Entitlement Offer
- Entitlement Offer to raise approximately $18.1 million
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
- Sponsored Research Agreement with University of Pennsylvania
Later from Chimeric Therapeutics
- Security Class Suspension from Quotation CHMO
- Completion of retail component of Entitlement Offer
- CDH17 car t preclinical data featured in nature cancer
- Security Class Reinstatement to Quotation CHMO
- Strategic manufacturing partnership with WuXi ATU
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics